Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,183.46 +1.57 (+0.13%)

Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

2025 R&D Spending And Intensity Benchmarks

September 09, 2026

Via PRLog

Topics Supply Chain

Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 ↗

September 09, 2026

Hint: It's a good idea to buy the stock today.

Via The Motley Fool

Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗

September 08, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗

September 08, 2026

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Via The Motley Fool

Topics Intellectual Property

If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗

September 08, 2026

Low-cost index funds can be a ticket to prosperity for everyday investors.

Via The Motley Fool

Topics ETFs Economy

Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back ↗

September 08, 2026

JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.

Via Benzinga

Topics ETFs

Why Is Eli Lilly Stock Falling Tuesday? ↗

September 08, 2026

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.

Via Benzinga

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗

September 08, 2026

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

Via Investor's Business Daily

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗

September 07, 2026

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Via The Motley Fool

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock ↗

September 06, 2026

Is this big pharma stock still a buy for investors who aren't billionaires?

Via The Motley Fool

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗

September 05, 2026

Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.

Via The Motley Fool

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years ↗

September 05, 2026

Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

Via The Motley Fool

Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. ↗

September 05, 2026

Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.

Via The Motley Fool

MarketBeat Week in Review – 08/31 - 09/04 ↗

September 05, 2026

Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks.

Via MarketBeat

Topics Artificial Intelligence Economy

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Via MarketBeat

If a Bear Market Is Coming, Is VOO or VTI the Safer Investment? ↗

September 04, 2026

You can't go wrong with either, but one has a key difference that gives it the edge.

Via The Motley Fool

Topics ETFs

2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗

September 04, 2026

You might regret ignoring these companies at current levels.

Via The Motley Fool

Topics Artificial Intelligence

Great News for Eli Lilly Stock Investors ↗

September 03, 2026

There is no end in sight for the company's incredible momentum.

Via The Motley Fool

Eli Lilly Just Announced a Major Acquisition. Here's What It Means. ↗

September 02, 2026

The drug giant added to its immunotherapy portfolio.

Via The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗

September 02, 2026

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Via The Motley Fool

Topics ETFs

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity ↗

September 02, 2026

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.

Via MarketBeat

Peptides Costa Rica Announces New Transparency Standard Amid Growing National Scrutiny of the Peptide Market

September 01, 2026

Jacó, Puntarenas - September 01, 2026 - Peptides Costa Rica has introduced a new transparency standard designed to give researchers and buyers clearer access to product verification information, a...

Via Press Advantage

Topics Supply Chain

Vanguard Health Care ETF vs Simplify Health Care ETF ↗

September 01, 2026

Vanguard offers broad exposure at 0.09% cost with 1.5% yield, while Simplify's active strategy returned 32.4% over one year but charges 0.51%.

Via The Motley Fool

Topics ETFs

This New Zepbound Study Could Be Great News for Eli Lilly Investors ↗

September 01, 2026

The high-flying healthcare leader looks unstoppable right now.

Via The Motley Fool

Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. ↗

August 31, 2026

Hardly for the first time recently, the company is making a pricey acquisition.

Via The Motley Fool

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. ↗

August 30, 2026

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Via The Motley Fool

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

3 Things That Matter Most for Eli Lilly Now ↗

August 29, 2026

Eli Lilly is the leader in the GLP-1 space, but the company can't rest on its laurels.

Via The Motley Fool

Topics Intellectual Property

Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? ↗

August 29, 2026

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.